Author details

Full Name

Lissandra Dal Lago

Affiliation

Institut Jules Bordet

ORCID

Career Start Year

2002

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
34625860	Correction to: Tolerability and toxicity of trastuzumab or trastuzumabâ¿¿+â¿¿lapatinib in older patients: a subâ¿¿analysis of the ALTTO trial (BIG 2â¿¿06; NCCTG (Alliance) N063D).	Breast Cancer Res Treat	2022
35636341	Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression.	Breast	2022
36202578	Use of information and communication technologies (ICTs) in cancer multidisciplinary team meetings: an explorative study based on EU healthcare professionals.	BMJ Open	2022
36358622	Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products: From Interactions to Synergic Activity.	Cancers (Basel)	2022
35924711	The efficacy of the American College of Surgeons Surgical Risk Calculator in the prediction of postoperative complications in oncogeriatric patients after curative surgery for abdominal tumors.	J Surg Oncol	2022
35101364	Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.	J Geriatr Oncol	2022
35239731	Evaluation of the Comprehensive Geriatric Assessment (CGA) tool as a predictor of postoperative complications following major oncological abdominal surgery in geriatric patients.	PLoS One	2022
34866400	The Managing Advanced Cancer Pain Together (MACPT) conversation tool: an evaluation of use in clinical practice.	Pain Manag	2022
32951084	Tolerability and toxicity of trastuzumab or trastuzumabâ¿¿+â¿¿lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).	Breast Cancer Res Treat	2021
33987121	Prostate Cancer and Reactive Haemophagocytic Lymphohistiocytosis.	Eur J Case Rep Intern Med	2021
34312396	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer.	NPJ Breast Cancer	2021
34226158	Targeted agents in older patients with gastrointestinal cancers - An overview.	J Geriatr Oncol	2021
31171494	Targeted therapy for breast cancer in older patients.	J Geriatr Oncol	2020
33585327	Rare Features of Dermatomyositis in a Patient with Ovarian Cancer.	Eur J Case Rep Intern Med	2020
32462916	Anti-HER2 therapy for breast cancer in older patients.	Future Oncol	2020
32541310	Use of granulocyte-colony stimulating factors in older patients: a review of recently published data.	Curr Opin Oncol	2020
32557904	The added value of geriatric assessment in evaluating a patient's Health-Related Quality-of-Life: A study in â¿¥70-year-old early-stage invasive breast cancer patients.	Eur J Cancer Care (Engl)	2020
30738289	Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study.	Breast	2019
32010204	Advances in pain management for older patients with cancer.	Ecancermedicalscience	2019
31235436	HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology.	J Geriatr Oncol	2019
29092024	Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.	Ann Oncol	2018
29433963	Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.	Lancet Oncol	2018
29167064	The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged â¿¥70 with early stage invasive breast cancer.	J Geriatr Oncol	2018
28130010	Old age: An extra risk for febrile neutropenia?	J Geriatr Oncol	2017
27102154	The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters.	Oncotarget	2016
27582270	What is the role of informed decision-making?	Expert Rev Anticancer Ther	2016
27454930	Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.	PLoS One	2016
27238734	Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.	J Geriatr Oncol	2016
27010772	Adjuvant chemotherapy in elderly patients with breast cancer: key challenges.	Expert Rev Anticancer Ther	2016
25725046	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)â¿ .	Ann Oncol	2015
26467471	Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).	Ann Oncol	2015
24495695	Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging?	J Geriatr Oncol	2014
24834120	Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.	Ecancermedicalscience	2014
24377816	Gastrin-releasing peptide receptor expression in lung cancer.	Arch Pathol Lab Med	2014
23871490	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.	Lancet	2013
24488382	Neoadjuvant chemotherapy and pathologic response: a retrospective cohort.	Einstein (Sao Paulo)	2013
22415797	Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?	Invest New Drugs	2012
21095116	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.	Eur J Cancer	2011
21570352	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.	Lancet Oncol	2011
17826917	Molecular-targeted therapies: lessons from years of clinical development.	Cancer Treat Rev	2008
18695262	Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.	Oncologist	2008
18178426	Current perspectives of epothilones in breast cancer.	Eur J Cancer	2008
16925482	Use of trastuzumab for the treatment of early stage breast cancer.	Expert Rev Anticancer Ther	2006
17010067	Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself.	Int J Gynecol Cancer	2006
17041102	Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.	Mol Cancer Ther	2006
16963260	What clinicians need to know about antioestrogen resistance in breast cancer therapy.	Eur J Cancer	2006
16962315	Multinational clinical trials in oncology and post-trial benefits for host countries: where do we stand?	Eur J Cancer	2006
16188441	Adjuvant chemotherapy in 2005: standards and beyond.	Breast	2005
15361178	Remaining controversies in the upfront management of advanced ovarian cancer.	Int J Gynecol Cancer	2004
14578685	Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.	Invest New Drugs	2003

1 - 50 of 51

Chiara Corti

University of Milano

Career Start Year 2017

Number of shared co-authors 1

Carmen Criscitiello

University of Milano

Career Start Year 2008

Number of shared co-authors 4

Stephen Welch

Victoria Hospital

Career Start Year 2007

Number of shared co-authors 0

Julia A Beaver

Center for Drug Evaluation and Research

Career Start Year 2007

Number of shared co-authors 3

Paul Hamberg

Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam

Career Start Year 2006

Number of shared co-authors 3

Sharon F McGee

The Ottawa Hospital Cancer Centre

Career Start Year 2006

Number of shared co-authors 0

Sara M Tolaney

Dana-Farber Cancer Institute

Career Start Year 2005

Number of shared co-authors 7

Aditya Bardia

Massachusetts General Hospital Cancer Center

Career Start Year 2004

Number of shared co-authors 4

David W Cescon

Princess Margaret Cancer Centre

Career Start Year 2003

Number of shared co-authors 4

Philippe L Bedard

Princess Margaret Cancer Centre, University Health Network

Career Start Year 2002

Number of shared co-authors 8

Matthew P Goetz

Mayo Clinic

Career Start Year 2002

Number of shared co-authors 7

Gregory R Pond

Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute

Career Start Year 2001

Number of shared co-authors 3

Hanneke W M van Laarhoven

Cancer Center Amsterdam

Career Start Year 2001

Number of shared co-authors 3

Ingrid A Mayer

Vanderbilt University Medical Center

Career Start Year 2000

Number of shared co-authors 5

Eleni Andreopoulou

New York Presbyterian Hospital

Career Start Year 1997

Number of shared co-authors 1

Katherine S Panageas

Memorial Sloan Kettering Cancer Center

Career Start Year 1996

Number of shared co-authors 1

Lillian L Siu

Princess Margaret Cancer Centre, University Ave

Career Start Year 1995

Number of shared co-authors 3

Stefan Sleijfer

Erasmus MC Cancer Institute, University Medical Center Rotterdam

Career Start Year 1994

Number of shared co-authors 5

Daniel Rea

Institute of Cancer and Genomic Sciences, The University of Birmingham

Career Start Year 1993

Number of shared co-authors 8

Vera J Suman

Mayo Clinic

Career Start Year 1992

Number of shared co-authors 2

Janet A Dunn

Warwick Clinical Trials Unit, University of Warwick

Career Start Year 1991

Number of shared co-authors 9

Ramona F Swaby

Merck & Co., Inc.

Career Start Year 1991

Number of shared co-authors 0

Val??rie Laurence

Institut Curie

Career Start Year 1990

Number of shared co-authors 0

Joan Albanell

Hospital del Mar Research Institute

Career Start Year 1990

Number of shared co-authors 8

Caroline Seynaeve

Erasmus Medical Center

Career Start Year 1990

Number of shared co-authors 12

Luc Dirix

GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp

Career Start Year 1988

Number of shared co-authors 14

Alberto Zambelli

IRCCS Humanitas Research Hospital

Career Start Year 1987

Number of shared co-authors 2

Chris Twelves

Leeds Teaching Hospitals NHS Trust, University of Leeds

Career Start Year 1986

Number of shared co-authors 6

Larry Norton

Memorial Sloan Kettering Cancer Center

Career Start Year 1976

Number of shared co-authors 8

Kathleen I Pritchard

UCL Great Ormond Street Institute of Child Health, University College London

Career Start Year 1976

Number of shared co-authors 9

row(s) 1 - 30 of 30

Fatima Cardoso

Champalimaud Clinical Center/Champalimaud Foundation

Co-authored papers 10

Christos Sotiriou

Co-authored papers 5

Coralie Poncet

Co-authored papers 4

Larissa A Korde

Clinical Investigations Branch, National Cancer Institute

Co-authored papers 4

Konstantinos Tryfonidis

Merck & Co., Inc.

Co-authored papers 3

Giuseppe Curigliano

University of Milan

Co-authored papers 3

Florentine S Hilbers

Netherlands Cancer Institute

Co-authored papers 3

Kim Benstead

Gloucestershire Hospitals NHS Foundation Trust

Co-authored papers 2

Joanna Vermeij

Hospital Network Antwerp (ZNA)

Co-authored papers 2

Carolien H M van Deurzen

Erasmus MC Cancer Institute

Co-authored papers 2

John W M Martens

Erasmus Medical Center (MC) Cancer Institute

Co-authored papers 2

Eric P Winer

Dana-Farber Cancer Institute

Co-authored papers 2

Lavinia P Middleton

The University of Texas MD Anderson Cancer Center

Co-authored papers 2

Stefan Aebi

University of Bern

Co-authored papers 2

A E van Leeuwen-Stok

Free University Hospital

Co-authored papers 2

Saskia Liti??re

Center for Statistics, Hasselt University

Co-authored papers 2

Aleksandra Peric

Co-authored papers 2

Jane Bayani

Ontario Institute for Cancer Research

Co-authored papers 2

John M S Bartlett

University of Edinburgh

Co-authored papers 2

Oliver B??gler

American Association for Cancer Research, Henry Ford Hospital, Ludwig Institute for Cancer Research, National Cancer Institute, Salk Institute for Biological Studies, University of Cambridge, University of Texas MD Anderson Cancer Center, Virginia Commonwealth University

Co-authored papers 2

Isabel T Rubio

Clinica Universidad de Navarra, Cancer Center Universidad de Navarra

Co-authored papers 2

Ingrid Hedenfalk

Lund University and Skane University Hospital

Co-authored papers 2

Peggy L Porter

Fred Hutchinson Cancer Research Center

Co-authored papers 2

Barbro Linderholm

Sahlgrenska University Hospital